Discovery and Optimization of Small Molecule Drug Leads and Probes
Event description
Join the UH Drug Discovery Institute for this hybrid event. A Zoom link will be emailed to registered attendees.
About the Event
John Buolamwini’s research entails multidisciplinary drug design and discovery and probe development, using synthetic medicinal chemistry, computer-aided molecular design, as well as biochemical, molecular biology, and experimental therapeutics methodologies. Disease areas of interest are ischemic heart disease, cancer and HIV/AIDS, and Alzheimer’s disease. Recent molecular targets include MDM2 oncoprotein, nucleoside transporters (hENTs/hCNTs), organic anion transporters (hOATs), and STAT3.
Buolamwini’s research has been funded continuously for over 25 years by agencies such as the American Heart Association, Alzheimer’s Research Association, Alzheimer’s Drug Discovery Foundation, and many National Institutes of Health (NIH) institutes, namely, NCI, NIGMS, NIAID, NIA, and NHLBI, through various grant mechanisms including R15s, R21s and RO1s, and STTR. His presentation will be highlighting past and recent results.
About the Speaker
John Buolamwini, Ph.D., is chair of Pharmaceutical Sciences at Rosalind Franklin University. He has held faculty positions in the United States for the past 30 years, including the University of Mississippi and the University of Tennessee, where he served as the Vice Chair and Director of Graduate Programs of the Department of Pharmaceutical Sciences from 2012-2014.
Tickets for good, not greed Humanitix dedicates 100% of profits from booking fees to charity